WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ ™ vancomycin oral solution kit by the FDA, today announced that it has been acquired by NovaQuest Capital Management, L.L.C. (“NovaQuest”). As a part of the transaction, Goldman Sachs Specialty Lending Group has provided financing to further support CutisPharma’s growth requirements. Financial terms were not disclosed. TAP Advisors acted as financial advisor to CutisPharma.
Product packaging and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates.
The Information contained herein, including product information, is intended only for residents of the United States.
© 2019-2024 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners.
PP-FKS-US-0095
